CN106309695A - 一种治疗前列腺疾病用中药透皮剂及其制备方法 - Google Patents
一种治疗前列腺疾病用中药透皮剂及其制备方法 Download PDFInfo
- Publication number
- CN106309695A CN106309695A CN201610741964.0A CN201610741964A CN106309695A CN 106309695 A CN106309695 A CN 106309695A CN 201610741964 A CN201610741964 A CN 201610741964A CN 106309695 A CN106309695 A CN 106309695A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- herba
- flos
- transdermal agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 208000017497 prostate disease Diseases 0.000 title abstract 2
- 241000628997 Flos Species 0.000 claims abstract description 62
- 239000000839 emulsion Substances 0.000 claims abstract description 39
- 238000010521 absorption reaction Methods 0.000 claims abstract description 31
- 239000003623 enhancer Substances 0.000 claims abstract description 28
- 241000663753 Aquilegia viridiflora Species 0.000 claims abstract description 21
- 241000448016 Stenoma Species 0.000 claims abstract description 21
- 241000028600 Youngia Species 0.000 claims abstract description 21
- 241001113271 Cremanthodium Species 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 239000007788 liquid Substances 0.000 claims description 39
- 238000000605 extraction Methods 0.000 claims description 30
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 26
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 26
- 241001247783 Meconopsis Species 0.000 claims description 21
- 235000021028 berry Nutrition 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 18
- -1 isopropyl ester Chemical class 0.000 claims description 16
- 241000208422 Rhododendron Species 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 150000003505 terpenes Chemical class 0.000 claims description 15
- 235000007586 terpenes Nutrition 0.000 claims description 15
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 claims description 13
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 13
- 244000045232 Canavalia ensiformis Species 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 235000010617 Phaseolus lunatus Nutrition 0.000 claims description 13
- 235000021355 Stearic acid Nutrition 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 13
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 13
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 13
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 13
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 239000008117 stearic acid Substances 0.000 claims description 13
- 239000003871 white petrolatum Substances 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 7
- 235000011152 sodium sulphate Nutrition 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 208000004880 Polyuria Diseases 0.000 abstract description 7
- 230000035619 diuresis Effects 0.000 abstract description 7
- 206010030113 Oedema Diseases 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 239000011159 matrix material Substances 0.000 abstract 3
- 241001072256 Boraginaceae Species 0.000 abstract 1
- 240000004995 Deeringia amaranthoides Species 0.000 abstract 1
- 241000686375 Elatostema cyrtandrifolium Species 0.000 abstract 1
- 241001047059 Meconopsis quintuplinervia Species 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 241001408429 Parameria Species 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000002585 base Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 14
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 201000007094 prostatitis Diseases 0.000 description 13
- 231100000614 poison Toxicity 0.000 description 10
- 239000003440 toxic substance Substances 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 6
- 208000008035 Back Pain Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000723353 Chrysanthemum Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010036018 Pollakiuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000700449 Philus antennatus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗前列腺疾病用中药透皮剂及其制备方法,包括乳剂基质、透皮吸收促进剂,所述乳剂基质与透皮吸收促进剂的质量比为18:1;所述乳剂基质由中药提取液、乳剂原料按照11:4的质量比构成;所述中药提取液中,各组分按重量份数,红花90‑110份、白花蛇舌草290‑310份、生地90‑110份、苦葵鸦葱70‑80份、绿花耧斗菜70‑80份、鸡挂骨草50‑60份、金丝藤仲50‑60份、浆果苋40‑48份、碱黄鹌菜40‑45份、五脉绿绒蒿花32‑40份、毛叶楼梯草30‑35份、齿缘草25‑30份、狭叶垂头菊25‑30份;其工艺流程较短,成本较低。本发明具有清热解毒、利水消肿、补肾安神等多种功效。
Description
技术领域
本发明涉及中药制剂领域,特别是涉及一种治疗前列腺疾病用中药透皮剂及其制备方法。
背景技术
前列腺增生和前列腺炎是男性前列腺的常见疾病。前列腺增生,是男性老年病人的常见疾病之一。随着年龄的增加,男人们或多或少都有前列腺增生的现象发生。有研究表明前列腺增生始于40岁以后,但60岁以上的老年人更为多见。我国已步入老龄社会,前列腺增生是老年男性的常见病和多发病。随全球人口老年化发病日渐增多。前列腺增生的发病率随年龄递增,城镇发病率高于乡村,而且种族差异也影响增生程度。其症状以排尿次数增多(尤其夜间)、排尿困难、尿流变细为主要特点。如气候变化、劳累、饮酒、房事或感染等诱因,极易引起尿潴留,甚至尿液完全排不出,造成极大痛苦。据统计,50岁以上的老年男性发病率约有30-50%,70-90岁的老年男性前列腺增生发病率为70%,80岁以上的约有90%以上患有此病,国内统计,前列腺增生约占泌尿外科住院病人的8%—11%。前列腺炎疾病有时和早泄同时出现,前列腺增生的主要症状有排尿困难,轻者夜里起床小便次数增多,有尿不净或尿完后还有少量排出的现象;严重者出现尿流变细,甚或排不出的现象;同时常伴有腰酸腰痛、四肢无力、遗精等症状。前列腺炎可分为急性及慢性。通常是由身体其他部位的细菌感染入侵前列腺所致。前列腺炎可完全或部分阻碍尿液由膀胱流出,导致尿液滞留。如此造成膀胱膨胀、衰弱、易受感染(因积存尿液里的细菌增加)。膀胱感染容易经由输尿管传至肾脏。急性前列腺炎的症状是阴囊到直肠之间疼痛、发烧、频尿且有灼热感,尿液含血或脓。慢性前列腺的症状则是频尿及灼热感,尿液带血、下半背痛、阳痿。前列腺炎愈严重,排尿愈困难。慢性前列腺炎患者常出现腰骶、会阴、睾丸等部位胀痛、尿不净、夜尿频等不良症状,还会影响患者的性功能和生育,严重影响男性同胞的正常工作和生活。而且慢性前列腺炎病程缓慢,顽固难治,在治疗过程中容易引起慢性肾炎等其他并发症,给患者带来沉重的精神负担,严重危害男性同胞的身体健康。
前列腺疾病已成为影响男性健康的常见病,困扰着许多男性,严重地影响了他们的生活质量,前列腺的保健已引起社会的广泛关注。虽然西医中存在着治疗前列腺疾病的药物,常见药物有抗生素、抗炎药、α受体阻滞剂、植物药、免疫抑制剂等。但是上述药物整体治疗效果不理想,而且易于复发,副作用较大,不适合病人长期使用;而在中药中,虽然也存在着一些治疗前列腺疾病的药物,但是其但针对性不强,疗效较慢。
发明内容
本发明的目的是提供一种治疗前列腺疾病用中药透皮剂及其制备方法,具有清热解毒、利水消肿、除湿利尿、补肾安神等多种功效,可以有效治愈前列腺增生、前列腺炎等前列腺疾病,并可以在一定程度上对前列腺疾病进行预防;其具有疗效确切、透过皮肤的速度和效率都较高、纯天然无毒副作用、刺激性小等多种优点。
本发明的目的通过以下技术方案来实现:
一种治疗前列腺疾病用中药透皮剂,包括乳剂基质、透皮吸收促进剂,所述乳剂基质与透皮吸收促进剂的质量比为18:1;所述乳剂基质由中药提取液、乳剂原料按照11:4的质量比构成;所述中药提取液中,各组分按重量份数,红花90-110份、白花蛇舌草290-310份、生地90-110份、苦葵鸦葱70-80份、绿花耧斗菜70-80份、鸡挂骨草50-60份、金丝藤仲50-60份、浆果苋40-48份、碱黄鹌菜40-45份、五脉绿绒蒿花32-40份、毛叶楼梯草30-35份、齿缘草25-30份、狭叶垂头菊25-30份。
作为优选的:
所述中药提取液中,各组分按重量份数,红花110份、白花蛇舌草310份、生地110份、苦葵鸦葱75份、绿花耧斗菜75份、鸡挂骨草55份、金丝藤仲55份、浆果苋40份、碱黄鹌菜40份、五脉绿绒蒿花32份、毛叶楼梯草30份、齿缘草25份、狭叶垂头菊25份。
作为优选的:
所述中药提取液中,各组分按重量份数,红花100份、白花蛇舌草300份、生地100份、苦葵鸦葱70份、绿花耧斗菜70份、鸡挂骨草50份、金丝藤仲50份、浆果苋48份、碱黄鹌菜45份、五脉绿绒蒿花40份、毛叶楼梯草35份、齿缘草30份、狭叶垂头菊30份。
作为优选的:
所述中药提取液中,各组分按重量份数,红花90份、白花蛇舌草290份、生地90、苦葵鸦葱80份、绿花耧斗菜80份、鸡挂骨草60份、金丝藤仲60份、浆果苋44份、碱黄鹌菜43份、五脉绿绒蒿花36份、毛叶楼梯草32份、齿缘草28份、狭叶垂头菊27份。
所述乳剂原料中,各组分按重量份数,单硬脂酸甘油酯70份、硬脂酸112。5份、甘油85份、白凡士林85份、十二烷基硫酸钠10份、对羟基苯甲酸钠1份。
所述透皮吸收促进剂由丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂构成按照1:4:2:1的质量比构成。
所述的一种治疗前列腺疾病用中药透皮剂,其制备方法的具体步骤为:
步骤1、备料:
(1)按重量份数,称取优质的中药提取液原料:红花、白花蛇舌草、生地、苦葵鸦葱、绿花耧斗菜、鸡挂骨草、金丝藤仲、浆果苋、碱黄鹌菜、五脉绿绒蒿花、毛叶楼梯草、齿缘草、狭叶垂头菊,洗净并除杂后,备用;
(2)按重量份数,称取优质的乳剂原料:单硬脂酸甘油酯、硬脂酸、甘油、白凡士林、十二烷基硫酸钠、对羟基苯甲酸钠,备用;
(3)按重量份数,称取优质的透皮吸收促进剂原料:丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂,备用;
步骤2、中药提取液的制备:
(1)取洗净并除杂后的红花、白花蛇舌草、生地、苦葵鸦葱、绿花耧斗菜、鸡挂骨草、金丝藤仲、浆果苋、碱黄鹌菜、五脉绿绒蒿花、毛叶楼梯草、齿缘草、狭叶垂头菊,混合均匀,得中药混合物,按料液比1:12的质量比加入纯净水,浸泡4-6小时后,煎煮1.5小时,过滤,取滤液;滤渣加入8倍的水,煎煮1小时后,过滤取滤液;滤渣加入6倍的水,煎煮0.5小时后,过滤;混合三次滤液后,采用微孔过滤膜过滤,得过滤液,将过滤液置于真空浓缩机中,浓缩至中药混合物的重量份后,制得中药提取液;
步骤3、乳剂基质的制备:
(1)按重量份数,称取乳剂原料中的单硬脂酸甘油酯、硬脂酸、甘油、白凡士林、十二烷基硫酸钠、对羟基苯甲酸钠,备用;
(2)按中药提取液、乳剂原料按照11:4的质量比,称取中药提取液,备用;
(3)取备用的单硬脂酸甘油酯、硬脂酸、白凡士林,置于煎煮容器内部,加热熔化的同时,混合搅拌均匀,并保持加热温度为80℃,得油相,备用;
(4)取十二烷基硫酸钠、甘油,置于另一煎煮容器内,混合搅拌均匀后,加入备用的中药提取液,再次混合搅拌均匀,并加热至80℃,加入对羟基苯甲酸钠,溶解后,加入备用的油相,按同一方向搅拌呈白色细膏状,冷却后备用;
步骤4、透皮吸收促进剂的制备:
按质量比,取丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂,置于混合容器内部,混合搅拌均匀,制得透皮吸收促进剂,备用;
步骤5、透皮剂的制备:
按质量比,称取乳剂基质、透皮吸收促进剂,置于煎煮容器内,底温加热,持续搅拌混合,混合均匀后,晾置2-4小时,冷却后,得到一种治疗前列腺疾病用中药透皮剂。
所述透皮剂中还包括薄荷粉30份。
在中药提取液的原料中:
红花,具有活血通经,散瘀止痛之功效,用于经闭,痛经,恶露不行,症瘕痞块,胸痹心痛,瘀滞腹痛,胸胁刺痛,跌扑损伤,疮疡肿痛,白花蛇舌草,清热解毒,利湿通淋,用于肺热喘咳,咽喉肿痛,肠痈,疖肿疮疡,毒蛇咬伤,热淋涩痛,水肿,痢疾,肠炎,湿热黄疸,癌肿,生地,清热凉血、益阴生津;苦葵鸦葱,清热解毒,消肿散结;绿花耧斗菜,调经止血,清热解毒,鸡挂骨草,清热解毒,凉血止血,治肺结核咳血,吐血,急性胃肠炎,金丝藤仲,补肾壮腰;散瘀止痛,主肾虚腰痛;筋骨疼痛;跌打损伤;浆果苋,祛风除湿、通经活络,治风湿性关节炎,风湿腰腿痛等,碱黄鹌菜,具有清热解毒,消肿止痛之功效;五脉绿绒蒿花,清热泻火,治肝炎,胆囊炎,肺炎,肺结核,胃溃疡,毛叶楼梯草,祛风除湿;解毒杀虫,主风湿痹痛;痈肿;疥疮;齿缘草,清温解热,治感冒温热病,脉管炎,狭叶垂头菊,清热解毒,主疮疡疖肿;肺痈;乳痈;肠痈;热病高热;热结便秘。
本发明的有益效果:本发明的一种治疗前列腺疾病用中药透皮剂,具有清热解毒、利水消肿、除湿利尿、补肾安神等多种功效,可以有效治愈前列腺增生、前列腺炎等前列腺疾病,并可以在一定程度上对前列腺疾病进行预防,从而大大提高男性的生活质量;并且其可以有效解决现有技术中西药治疗具有一定的副作用与中药治疗药效缓慢、药物吸收效果较差的问题;其具有疗效确切、透过皮肤的速度和效率都较高、纯天然无毒副作用、刺激性小等多种优点;其制备工艺科学、合理、有效,工艺流程较短,成本较低,适于工业化生产,具有极高的社会效益与经济效益。
本发明的一种治疗前列腺疾病用中药透皮剂,将祖传配方与多次实验相结合,最终采用红花、白花蛇舌草、生地、苦葵鸦葱、绿花耧斗菜、鸡挂骨草、金丝藤仲、浆果苋、碱黄鹌菜、五脉绿绒蒿花、毛叶楼梯草、齿缘草、狭叶垂头菊等十余味中药制成,制备出了一种具有清热解毒、利水消肿、除湿利尿、补肾安神等多种功效,可以有效有效治愈前列腺增生、前列腺炎等前列腺疾病的药剂,其组分科学、合理配伍,互相支持,有效用于治疗前列腺疾病,用药安全,并经临床治疗得到了充分证明;并且在药剂中加入了由丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂构成按照1:4:2:1的最佳质量比制备而成的透皮吸收促进剂,使得本药剂在与皮肤接触使用时,药剂透过皮肤的速度和效率都较高,从而使透皮吸收药物的效果较好。
在本发明中,还可以添加适量的薄荷粉,可以有效改善本发明的药味。
在透皮吸收促进剂中,杜香萜烯是从狭叶杜香中提取的一种新的天然透皮吸收促进剂,它不仅具有较好的促渗作用,而且还具有良好的稳定性和生物膜惰性,杜香萜烯能够对角质层类脂双分子层产生干扰并导致其变成无序状态,改变角质层的构象,松弛它们之间的结合力导致形成微细孔道,从而提高极性药物在细胞内通道的渗透性;丙二醇能渗入角质层并在其中形成蓄积,增加药物在角质层中的溶解性和分配性质。但单独应用的效果往往不佳,如果与其他的促进剂合用则可在起到增加药物及促进剂溶解度的同时发挥协同作用;杜香萜烯与丙二醇体现了较好的协同作用;癸基甲基亚砜在低浓度时就有促进作用,对极性药物的促渗能力大于非极性药物;肉豆蒄酸异丙脂,对皮肤有极好的渗透、滋润和软化作用;将由丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂构成按照1:4:2:1的最佳质量比混合制备而成的透皮吸收促进剂,使得药剂透过皮肤的速度、效率、效果都更好。
临床观察资料
临床试验观察,成人使用本发明的透皮剂;临床试验结果见表1、表2;
表1本发明的透皮剂治疗前列腺炎患者主要症候的疗效;
本发明的透皮剂治疗前列腺炎200例的总有效率为100%,临床观察对其主要症候的改善疗效显著,如阴部胀痛、小腹拘急、腰隐痛及小便淋漓、涩痛的有效率均达到90%以上;
表2本发明的透皮剂治疗前列腺炎患者主要症候的疗效;
本发明的透皮剂治疗前列腺增生150例,临床总有效率达100%,对改善前列腺增生的主要症候如夜尿频数、滴沥不净、排尿不畅、小便涩痛等总有效率均在85.0%以上。
本发明的透皮剂治疗前列腺炎、前列腺增生从临床试验结果显示其疗效较为满意。
具体实施方式
实施例1
一种治疗前列腺疾病用中药透皮剂,包括乳剂基质、透皮吸收促进剂,所述乳剂基质与透皮吸收促进剂的质量比为18:1;所述乳剂基质由中药提取液、乳剂原料按照11:4的质量比构成;所述中药提取液中,各组分按重量份数,红花90-110份、白花蛇舌草290-310份、生地90-110份、苦葵鸦葱70-80份、绿花耧斗菜70-80份、鸡挂骨草50-60份、金丝藤仲50-60份、浆果苋40-48份、碱黄鹌菜40-45份、五脉绿绒蒿花32-40份、毛叶楼梯草30-35份、齿缘草25-30份、狭叶垂头菊25-30份。
实施例2
所述中药提取液中,各组分按重量份数,红花110份、白花蛇舌草310份、生地110份、苦葵鸦葱75份、绿花耧斗菜75份、鸡挂骨草55份、金丝藤仲55份、浆果苋40份、碱黄鹌菜40份、五脉绿绒蒿花32份、毛叶楼梯草30份、齿缘草25份、狭叶垂头菊25份。
实施例3
所述中药提取液中,各组分按重量份数,红花100份、白花蛇舌草300份、生地100份、苦葵鸦葱70份、绿花耧斗菜70份、鸡挂骨草50份、金丝藤仲50份、浆果苋48份、碱黄鹌菜45份、五脉绿绒蒿花40份、毛叶楼梯草35份、齿缘草30份、狭叶垂头菊30份。
实施例4
所述中药提取液中,各组分按重量份数,红花90份、白花蛇舌草290份、生地90、苦葵鸦葱80份、绿花耧斗菜80份、鸡挂骨草60份、金丝藤仲60份、浆果苋44份、碱黄鹌菜43份、五脉绿绒蒿花36份、毛叶楼梯草32份、齿缘草28份、狭叶垂头菊27份。
实施例5
所述乳剂原料中,各组分按重量份数,单硬脂酸甘油酯70份、硬脂酸112。5份、甘油85份、白凡士林85份、十二烷基硫酸钠10份、对羟基苯甲酸钠1份。
实施例6
所述透皮吸收促进剂由丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂构成按照1:4:2:1的质量比构成。
实施例7
所述的一种治疗前列腺疾病用中药透皮剂,其制备方法的具体步骤为:
步骤1、备料:
(1)按重量份数,称取优质的中药提取液原料:红花、白花蛇舌草、生地、苦葵鸦葱、绿花耧斗菜、鸡挂骨草、金丝藤仲、浆果苋、碱黄鹌菜、五脉绿绒蒿花、毛叶楼梯草、齿缘草、狭叶垂头菊,洗净并除杂后,备用;
(2)按重量份数,称取优质的乳剂原料:单硬脂酸甘油酯、硬脂酸、甘油、白凡士林、十二烷基硫酸钠、对羟基苯甲酸钠,备用;
(3)按重量份数,称取优质的透皮吸收促进剂原料:丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂,备用;
步骤2、中药提取液的制备:
(1)取洗净并除杂后的红花、白花蛇舌草、生地、苦葵鸦葱、绿花耧斗菜、鸡挂骨草、金丝藤仲、浆果苋、碱黄鹌菜、五脉绿绒蒿花、毛叶楼梯草、齿缘草、狭叶垂头菊,混合均匀,得中药混合物,按料液比1:12的质量比加入纯净水,浸泡4-6小时后,煎煮1.5小时,过滤,取滤液;滤渣加入8倍的水,煎煮1小时后,过滤取滤液;滤渣加入6倍的水,煎煮0.5小时后,过滤;混合三次滤液后,采用微孔过滤膜过滤,得过滤液,将过滤液置于真空浓缩机中,浓缩至中药混合物的重量份后,制得中药提取液;
步骤3、乳剂基质的制备:
(1)按重量份数,称取乳剂原料中的单硬脂酸甘油酯、硬脂酸、甘油、白凡士林、十二烷基硫酸钠、对羟基苯甲酸钠,备用;
(2)按中药提取液、乳剂原料按照11:4的质量比,称取中药提取液,备用;
(3)取备用的单硬脂酸甘油酯、硬脂酸、白凡士林,置于煎煮容器内部,加热熔化的同时,混合搅拌均匀,并保持加热温度为80℃,得油相,备用;
(4)取十二烷基硫酸钠、甘油,置于另一煎煮容器内,混合搅拌均匀后,加入备用的中药提取液,再次混合搅拌均匀,并加热至80℃,加入对羟基苯甲酸钠,溶解后,加入备用的油相,按同一方向搅拌呈白色细膏状,冷却后备用;
步骤4、透皮吸收促进剂的制备:
按质量比,取丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂,置于混合容器内部,混合搅拌均匀,制得透皮吸收促进剂,备用;
步骤5、透皮剂的制备:
按质量比,称取乳剂基质、透皮吸收促进剂,置于煎煮容器内,底温加热,持续搅拌混合,混合均匀后,晾置2-4小时,冷却后,得到一种治疗前列腺疾病用中药透皮剂。
实施例8
所述透皮剂中还包括薄荷粉30份。
实施例9
一种治疗前列腺疾病用中药透皮剂,包括乳剂基质、透皮吸收促进剂,所述乳剂基质与透皮吸收促进剂的质量比为18:1;所述乳剂基质由中药提取液、乳剂原料按照11:4的质量比构成;
所述中药提取液中,红花100g、白花蛇舌草300g、生地100g、苦葵鸦葱70g、绿花耧斗菜70g、鸡挂骨草50g、金丝藤仲50g、浆果苋48g、碱黄鹌菜45g、五脉绿绒蒿花40g、毛叶楼梯草35g、齿缘草30g、狭叶垂头菊30份;
所述乳剂原料中,单硬脂酸甘油酯70g、硬脂酸112。5g、甘油85g、白凡士林85g、十二烷基硫酸钠10g、对羟基苯甲酸钠1g;
所述透皮吸收促进剂由丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂构成按照1:4:2:1的质量比构成。
Claims (8)
1.一种治疗前列腺疾病用中药透皮剂,包括乳剂基质、透皮吸收促进剂,其特征在于:所述乳剂基质与透皮吸收促进剂的质量比为18:1;所述乳剂基质由中药提取液、乳剂原料按照11:4的质量比构成;所述中药提取液中,各组分按重量份数,红花90-110份、白花蛇舌草290-310份、生地90-110份、苦葵鸦葱70-80份、绿花耧斗菜70-80份、鸡挂骨草50-60份、金丝藤仲50-60份、浆果苋40-48份、碱黄鹌菜40-45份、五脉绿绒蒿花32-40份、毛叶楼梯草30-35份、齿缘草25-30份、狭叶垂头菊25-30份。
2.根据权利要求1所述的一种治疗前列腺疾病用中药透皮剂,其特征在于:所述中药提取液中,各组分按重量份数,红花110份、白花蛇舌草310份、生地110份、苦葵鸦葱75份、绿花耧斗菜75份、鸡挂骨草55份、金丝藤仲55份、浆果苋40份、碱黄鹌菜40份、五脉绿绒蒿花32份、毛叶楼梯草30份、齿缘草25份、狭叶垂头菊25份。
3.根据权利要求1所述的一种治疗前列腺疾病用中药透皮剂,其特征在于:所述中药提取液中,各组分按重量份数,红花100份、白花蛇舌草300份、生地100份、苦葵鸦葱70份、绿花耧斗菜70份、鸡挂骨草50份、金丝藤仲50份、浆果苋48份、碱黄鹌菜45份、五脉绿绒蒿花40份、毛叶楼梯草35份、齿缘草30份、狭叶垂头菊30份。
4.根据权利要求1所述的一种治疗前列腺疾病用中药透皮剂,其特征在于:所述中药提取液中,各组分按重量份数,红花90份、白花蛇舌草290份、生地90、苦葵鸦葱80份、绿花耧斗菜80份、鸡挂骨草60份、金丝藤仲60份、浆果苋44份、碱黄鹌菜43份、五脉绿绒蒿花36份、毛叶楼梯草32份、齿缘草28份、狭叶垂头菊27份。
5.根据权利要求1所述的一种治疗前列腺疾病用中药透皮剂,其特征在于:所述乳剂原料中,各组分按重量份数,单硬脂酸甘油酯70份、硬脂酸112.5份、甘油85份、白凡士林85份、十二烷基硫酸钠10份、对羟基苯甲酸钠1份。
6.根据权利要求1所述的一种治疗前列腺疾病用中药透皮剂,其特征在于:所述透皮吸收促进剂由丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂构成按照1:4:2:1的质量比构成。
7.根据权利要求1-6任意一项所述的一种治疗前列腺疾病用中药透皮剂,其特征在于:其制备方法的具体步骤为:
步骤1、备料:
(1)按重量份数,称取优质的中药提取液原料:红花、白花蛇舌草、生地、苦葵鸦葱、绿花耧斗菜、鸡挂骨草、金丝藤仲、浆果苋、碱黄鹌菜、五脉绿绒蒿花、毛叶楼梯草、齿缘草、狭叶垂头菊,洗净并除杂后,备用;
(2)按重量份数,称取优质的乳剂原料:单硬脂酸甘油酯、硬脂酸、甘油、白凡士林、十二烷基硫酸钠、对羟基苯甲酸钠,备用;
(3)按重量份数,称取优质的透皮吸收促进剂原料:丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂,备用;
步骤2、中药提取液的制备:
(1)取洗净并除杂后的红花、白花蛇舌草、生地、苦葵鸦葱、绿花耧斗菜、鸡挂骨草、金丝藤仲、浆果苋、碱黄鹌菜、五脉绿绒蒿花、毛叶楼梯草、齿缘草、狭叶垂头菊,混合均匀,得中药混合物,按料液比1:12的质量比加入纯净水,浸泡4-6小时后,煎煮1.5小时,过滤,取滤液;滤渣加入8倍的水,煎煮1小时后,过滤取滤液;滤渣加入6倍的水,煎煮0.5小时后,过滤;混合三次滤液后,采用微孔过滤膜过滤,得过滤液,将过滤液置于真空浓缩机中,浓缩至中药混合物的重量份后,制得中药提取液;
步骤3、乳剂基质的制备:
(1)按重量份数,称取乳剂原料中的单硬脂酸甘油酯、硬脂酸、甘油、白凡士林、十二烷基硫酸钠、对羟基苯甲酸钠,备用;
(2)按中药提取液、乳剂原料按照11:4的质量比,称取中药提取液,备用;
(3)取备用的单硬脂酸甘油酯、硬脂酸、白凡士林,置于煎煮容器内部,加热熔化的同时,混合搅拌均匀,并保持加热温度为80℃,得油相,备用;
(4)取十二烷基硫酸钠、甘油,置于另一煎煮容器内,混合搅拌均匀后,加入备用的中药提取液,再次混合搅拌均匀,并加热至80℃,加入对羟基苯甲酸钠,溶解后,加入备用的油相,按同一方向搅拌呈白色细膏状,冷却后备用;
步骤4、透皮吸收促进剂的制备:
按质量比,取丙二醇、杜香萜烯、癸基甲基亚砜、肉豆蒄酸异丙脂,置于混合容器内部,混合搅拌均匀,制得透皮吸收促进剂,备用;
步骤5、透皮剂的制备:
按质量比,称取乳剂基质、透皮吸收促进剂,置于煎煮容器内,底温加热,持续搅拌混合,混合均匀后,晾置2-4小时,冷却后,得到一种治疗前列腺疾病用中药透皮剂。
8.根据权利要求1-7任意一项所述的一种治疗前列腺疾病用中药透皮剂,其特征在于:所述透皮剂中还包括薄荷粉30份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610741964.0A CN106309695A (zh) | 2016-08-29 | 2016-08-29 | 一种治疗前列腺疾病用中药透皮剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610741964.0A CN106309695A (zh) | 2016-08-29 | 2016-08-29 | 一种治疗前列腺疾病用中药透皮剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106309695A true CN106309695A (zh) | 2017-01-11 |
Family
ID=57791159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610741964.0A Pending CN106309695A (zh) | 2016-08-29 | 2016-08-29 | 一种治疗前列腺疾病用中药透皮剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106309695A (zh) |
-
2016
- 2016-08-29 CN CN201610741964.0A patent/CN106309695A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205026B (zh) | 一种治疗小儿慢性鼻窦炎的中药组合物及其制备方法 | |
CN105709021A (zh) | 一种筋骨复原膏及其制备方法 | |
CN104826036A (zh) | 一种治疗乳腺增生的复合中药组合物及制备方法 | |
CN102512616B (zh) | 一种中草药祛痘组合物 | |
CN101318006B (zh) | 一种抗菌止痒中药外用护理制剂 | |
CN103495072B (zh) | 一种治疗支气管扩张病的中药组合物及其制备方法 | |
CN105412697A (zh) | 一种清热除湿、保肝利胆的佩兰口服液及其制备方法 | |
CN101099802A (zh) | 一种治疗骨质增生性疾病的外用搽剂 | |
CN104398925A (zh) | 一种治疗皮肤病的药物及其制备方法 | |
CN103961616A (zh) | 一种治疗过敏性咳嗽的药物及其制备方法 | |
CN107213360A (zh) | 一种治疗重型肌无力的中药组合物 | |
CN104971271A (zh) | 一种治疗瘀湿化热型前列腺增生的药物及制备方法 | |
CN105232788A (zh) | 一种用于治疗肝内胆汁淤积的中药 | |
CN106309695A (zh) | 一种治疗前列腺疾病用中药透皮剂及其制备方法 | |
CN104623559A (zh) | 消除乳房肿块的活血祛瘀药剂 | |
CN104758754A (zh) | 一种治疗肾气虚衰型前列腺增生的药物及制备方法 | |
CN104225348A (zh) | 一种治疗胆结石的中药 | |
CN103638422B (zh) | 一种治疗尿潴留的药物及其制备方法 | |
CN107789525A (zh) | 一种治疗臁疮溃疡多年不愈的药物及其制备方法 | |
CN105853843A (zh) | 一种临床用小儿伤口护理的药物组合物及其制备方法 | |
CN105688075A (zh) | 一种治疗腹痛的新型口服制剂及其制备方法 | |
CN105213946A (zh) | 一种治疗便秘的药物及其制备方法 | |
CN105031282A (zh) | 一种治疗小儿髋关节积液的药物及其制备方法 | |
CN104056225A (zh) | 一种治疗心房纤颤的药物及其制备方法 | |
CN103638411B (zh) | 一种治疗淋巴结核的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |
|
RJ01 | Rejection of invention patent application after publication |